Weed Inc (OTC: BUDZ) is a pre-revenue cannabis research and development company focused on the study, genomic classification, and potential pharmaceutical application of cannabis-derived compounds. The company has not generated any significant revenue as of the fiscal year ended December 31, 2025, and its auditors have issued a going concern qualification citing recurring operating losses, negative cash flows, and an accumulated deficit. WEED operates through three subsidiaries: Sangre AT, LLC, which conducts cannabis genomic research including a pilot study completed in 2017-2018 at the University of Texas-Galveston covering 30 cultivars; WEED Israel Cannabis Ltd., which partners with the Hebrew University of Jerusalem on clinical trials and cannabinoid delivery formulations; and Four Winds Lake Erie, LLC, which holds approximately 44 acres of property in Portland, New York acquired in November 2021 for $477,000, intended for hemp and infused beverage markets. The company holds an exclusive license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem for lipophilic cannabinoid delivery technologies developed by Professor Elka Touitou.

Revenue model

The company has not generated significant revenue as of fiscal year ended December 31, 2025. No commercial revenue streams are disclosed in the filing. Operations are funded through notes payable, including related-party notes, and equity issuances.

Products and services

Cannabis genomic research (30-cultivar pilot study completed 2017-2018 at University of Texas-Galveston); cannabinoid delivery platform technologies licensed from Yissum Research Development Company of the Hebrew University of Jerusalem (exclusive license signed March 1, 2019); planned clinical human trials through WEED Israel Cannabis Ltd.; planned hemp and infused beverage products through Four Winds Lake Erie, LLC; grower license and trademark recorded as intangible assets on the balance sheet.

Customers and end markets

No commercial customers disclosed. Target end markets described in the filing include pharmaceutical-grade medical cannabis for human disease and animal ailments, infused beverages, and hemp products in New York. The company describes its intended customers as patients, doctors, and health practitioners.

Value-chain role

Early-stage cannabis research and IP development. The company sits at the pre-commercial research stage, conducting genomic studies and licensing delivery technology with the goal of eventual pharmaceutical product development. No manufacturing, distribution, or retail operations are currently active.

Geographic exposure

United States (Texas research, New York property) and Israel (WEED Israel Cannabis Ltd., partnerships with Hebrew University of Jerusalem). No revenue-generating operations confirmed in any geography as of fiscal year ended December 31, 2025.

Competitors

Canopy Growth Corporation (TSX: WEED.TO / NASDAQ: CGC), Aurora Cannabis (TSX: ACB / NASDAQ: ACB), Cronos Group (TSX: CRON / NASDAQ: CRON), Trulieve Cannabis Corp (CSE: TRUL / OTCQX: TCNNF), TerrAscend Corporation (OTCQX: TRSSF), Tilray Brands Inc (NASDAQ: TLRY)

Source: SEC 10-K, filed 2026-04-08

Industry: Services-Commercial Physical & Biological Research Peers: Aytu Biopharma Inc Barrel Energy Inc. cbdMD Inc Hoth Therapeutics Inc Jaguar Health Inc Johnson & Johnson Vyne Therapeutics Inc Pulmatrix Inc Unrivaled Brands, Inc. Virpax Pharmaceuticals, Inc.